Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | HTR1A | P08908 | 13/20 | 1.00 |
| ▸ | HTR7 | P34969 | 6/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383152 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| SCHEMBL29772995 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| Hydrochloric Acid SCHEMBL29444972 | 0.99 | ADRB2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| SCHEMBL4464192 | 0.88 | DRD2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| SCHEMBL4460956 | 0.87 | DRD2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| SCHEMBL4462276 | 0.87 | DRD2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| SCHEMBL4458829 | 0.86 | DRD2 (1.00) | DRD2HTR1AHTR7 | |
| SCHEMBL4463626 | 0.85 | HTR1A (1.00) | DRD2HTR1AHTR7 | |
| SCHEMBL29358955 | 0.85 | DRD2 (1.00) | DRD2HTR1AHTR7MTORRAB9A | |
| SCHEMBL4558419 | 0.84 | DRD2 (0.79) | DRD2HTR1AHTR7MTORRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2021030571-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-18 | — | — | WO | claimed |
| US-7488730-B2 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-02-10 | — | — | US | claimed |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2007-05-24 | — | — | US | claimed |
| US-20230000885-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030571-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-18 | — | — | WO | disclosed |
| US-7488730-B2 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-02-10 | — | — | US | disclosed |
| US-7488730-B2 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-02-10 | — | — | US | disclosed |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2007-05-24 | — | — | US | disclosed |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | HTR7, HTR3A, HTR1E | DRD2 187/4885HTR1A 5/4885HTR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.